Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
April 27, 2022 at 02:55 pm IST
Share
Jiangsu Sihuan Bioengineering Co., Ltd reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 340.08 million compared to CNY 501.61 million a year ago. Revenue was CNY 350.96 million compared to CNY 505.4 million a year ago. Net loss was CNY 34.79 million compared to net income of CNY 27.3 million a year ago. Basic loss per share was CNY 0.0338 compared to basic earnings per share of CNY 0.0265 a year ago. Diluted loss per share was CNY 0.0338 compared to diluted earnings per share of CNY 0.0265 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
